FDA lifts clinical hold on Foghorn’s study for blood and bone marrow cancer treatment

Tyler Patchen

News Reporter

Foghorn Therapeutics, a gene-focused biotech, has been given the all-clear to proceed with a trial assessing its therapy aimed at treating cancers found in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts clinical hold on Foghorn’s study for blood and bone marrow cancer treatment

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Breaking down silos with a new quantitative approach to drug development

FDA lifts clin­i­cal hold on Foghorn’s study for blood and bone mar­row can­cer treat­ment

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA lifts clinical hold on Foghorn’s study for blood and bone marrow cancer treatment